Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, New Horizon Health's enterprise value is €702.8 Mil.
New Horizon Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €0.8 Mil. Therefore, New Horizon Health's EV-to-EBITDA for today is 830.75.
The historical rank and industry rank for New Horizon Health's EV-to-EBITDA or its related term are showing as below:
FRA:6YZ's EV-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 13.63 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
New Horizon Health (FRA:6YZ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
New Horizon Health's PE Ratio (TTM) for today is calculated as:
New Horizon Health's share price for today is €1.62.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. New Horizon Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €0.029.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for New Horizon Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, New Horizon Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Horizon Health EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, New Horizon Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where New Horizon Health's EV-to-EBITDA falls into.
New Horizon Health's current Enterprise Value is €702.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. New Horizon Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €0.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Horizon Health (FRA:6YZ) has a EV-to-EBITDA of 830.75 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on New Horizon Health.
Is New Horizon Health's EV-to-EBITDA too high?
New Horizon Health's current EV-to-EBITDA is 830.75. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.63. New Horizon Health's value of 830.75 is 5995% above this industry median. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's EV-to-EBITDA compare to ABT and SYK?
New Horizon Health's EV-to-EBITDA of 830.75 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-EBITDA is 13.63. New Horizon Health's value of 830.75 is 5995% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.63, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. New Horizon Health's current EV-to-EBITDA of 830.75 is 5995% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on New Horizon Health. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Horizon Health's current EV-to-EBITDA is 830.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (FRA:6YZ) has a current EV-to-EBITDA of 830.75. The current EV-to-EBITDA is 830.75 and 5995% above the Medical Devices & Instruments industry median of 13.63. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For New Horizon Health (FRA:6YZ), the current EV-to-EBITDA is 830.75 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
35GF Score
Get the complete analysis for FRA:6YZ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YZ has been successfully added to your 
